Management of a Refractory Malignant Pleural Effusion in a Patient with Small Cell Lung Cancer: A Case Report

Maria M Wilczynska1* and Helen E Davies2

1Department of Respiratory Medicine, Forth Valley Royal Hospital, UK
2Department of Respiratory Medicine, University Hospital of Llandough, UK

*Corresponding author: Maria M Wilczynska, Department of Respiratory Medicine, Forth Valley Royal Hospital, Stirling Road, Larbert FK5 4WR, UK, E-mail: mwilczynska@doctors.org.uk

Abstract

Malignant pleural effusion (MPE) is a common presenting feature of underlying malignancy and frequently results in debilitating symptoms. In chemosensitive malignancies, such as lymphoma, small cell lung or ovarian cancers, chemotherapy is often considered the first line treatment, however if unsuccessful, pleural intervention to achieve fluid control is required. This may include therapeutic thoracentesis, chest drain insertion, thoracoscopy, chemical pleurodesis, and use of an ambulatory indwelling pleural catheter (IPC) or a combination of the above procedures.

Our case describes the management of a patient with a refractory MPE secondary to metastatic small cell lung cancer. No consensus exists to guide the management of patients with MPE secondary to chemosensitive disease and a personalised strategy should be adopted. Patients should be informed of all currently available therapeutic options, and further research performed focusing on the effect of these approaches, in combination with palliative chemotherapy, on patient related outcome measures.

Keywords

Indwelling pleural catheter, Lung cancer, Pleural effusion, Thoracentesis

Introduction

Lung cancer is the most common cause of malignant pleural effusion (MPE) followed by carcinoma of the breast. These malignancies account for 50-65% of all malignant effusions. Lymphoma, ovarian and stomach cancer account for a further 25%. Median survival in patients with MPE ranges from 3-12 months, varying with tumour type and stage [1].

Although small cell lung cancer (SCLC), lymphoma, ovarian and breast cancer classically respond to chemotherapy, associated recurrent symptomatic MPE may require additional intervention during the course of patients’ treatment. Options for management include observation, therapeutic pleural aspiration, and intercostal tube drainage with instillation of sclerosant, thorascoposcopic pleurodesis and placement of an indwelling pleural catheter (IPC).

Our case highlights a clinical scenario and encountered therapeutic dilemmas commonly faced by physicians managing patients with a MPE resultant from chemosensitive disease.

Case Presentation

A 69-year-old female presented with a 3-month history of a cough, three weeks of worsening breathlessness and generalised left arm pain. She was otherwise well with no anorexia or weight loss. She had no significant co-morbidities but was a current smoker of 20 cigarettes daily having accumulated a 30 pack year history; there was no history of asbestos exposure. At presentation, the patient was still working as a school cleaner. Her breathlessness was not limiting functional capabilities.

On initial examination, a swollen, engorged left arm with dilated superficial veins was noted. The latter was also evident on the anterior left chest wall. There was no upper limb neuro-vascular compromise. On chest auscultation, breath sounds were reduced with a reduced percussion note throughout left hemithorax.

Chest radiography and subsequent thoracic ultrasonography confirmed a moderate echogenic left-sided pleural effusion. Computed tomography imaging showed a 7cm left apical mass encasing the subclavian vessels; a central nodal mass occluding the left main bronchus, and a left pleural effusion (Figure 1). Radiologically, the patient had advanced primary bronchogenic carcinoma (stage 4; T4 N2 M1a). A diagnostic pleural aspiration was cytologically positive confirming metastatic small cell lung cancer.

The patient’s case was discussed with the lung cancer multidisciplinary team, and referral for chemotherapy made. She received four cycles of palliative carboplatin and etoposide with a good radiological and clinical response to treatment - her tumour burden lessened and the pleural effusion resolved. Consolidation thoracic radiotherapy (5 fractions of 20 Gy) and prophylactic cranial irradiation were therefore administered.

Five months after the initial treatment, the patient developed worsening dyspnoea. A chest x-ray confirmed recurrence of pleural effusion. She was admitted to a local hospital where an intercostal
chest drain was inserted. Her symptoms improved and an x-ray the following day confirmed lung re-expansion with pleural apposition. Talc pleurodesis was performed with instillation of 4g of sterile talc slurry. Second-line chemotherapy with cyclophosphamide, doxorubicin, and vincristine was started, however, was discontinued after the first cycle as her symptoms worsened. Repeat imaging revealed recurrence of the left pleural effusion. Therapeutic options were discussed and an IPC was inserted. This resulted in significant improvement in breathlessness and quality of life.

Our patient gained independence through self-management of her IPC. She lived another four months and spent this time with family and community palliative care team support.

Discussion

MPE is a common clinical problem and is a frequent presenting feature of metastatic malignancy. Over 1 million people in Europe develop a MPE from lung cancer alone [2]. The burden of MPE continues to grow as the population’s life expectancy rises, oncological therapies advance and cancer rates increase. The predicted human cost for patients with a MPE, with a median survival of 3 months, is significant.

Palliation of common symptoms of MPE, such as breathlessness, cough and chest pain; with the improvement of patient related outcome measures, should be foremost in MPE patient management. Early pharmacological treatment alongside pleural intervention is frequently required.

In patients with the chemosensitive disease, systemic chemotherapy may resolve the pleural effusion, as in the featured case; however after an initial response, pleural fluid may re-accumulate.

When considering treatment options, patients’ symptoms, expectations and wishes, their performance status and life expectancy; and the nature of their underlying malignancy should be taken into account. In all cases, alleviation of symptoms to achieve improvement in patients’ quality of life is paramount.

Most recent treatment algorithms for MPE advocate that if there is response to initial therapeutic pleural aspiration and there is no evidence of trapped lung on CT thorax several therapeutic intervention could be undertaken as the first line treatment depending on patient’s choice and predicted life expectancy. It could be medical pleurodesis, thoracoscopy with a sclerosant instillation, or placement of an IPC [3].

Therapeutic pleural aspiration

At presentation pleural fluid aspiration can be performed for diagnostic and therapeutic purpose. Cytological analysis of pleural fluid provides a diagnostic sensitivity of approximately 60% although this is higher in certain malignancies e.g. adenocarcinoma than others e.g. mesothelioma. Although therapeutic (large volume) thoracentesis can be readily performed; between 98-100% of patients experience fluid re-accumulation with associated symptoms within 30 days and the procedure is not without risk [3].

Pleurodesis

Pleurodesis is the iatrogenic fusion of the pleural surfaces to prevent the accumulation of fluid or air. It may be performed chemically through instillation of a sclerosant into the pleural cavity, or mechanically through thoracoscopic pleural abrasion or parietal pleurectomy. The latter are seldom indicated in patients with MPE. Prior to performing pleurodesis a chest drain is sited and the effusion drained. Pleural apposition is a prerequisite for successful pleurodesis and, if this is not seen or the lung is ‘trapped’, pleurodesis is contraindicated [1]. Talc is the favoured (and most effective) sclerosant worldwide; an observation supported by a recent Cochrane review [4].

Thoracoscopy

Thoracoscopy is another therapeutic procedure that can be performed under local anaesthesia in patients with MPE. It allows for lysis of adhesions and administration of chemical sclerosants before a chest drain is placed [3]. Two randomised controlled trials

Figure 1: (A) Chest radiograph on presentation showing complete whiteout of left hemithorax the central location of the trachea concurs with the presence of underlying lung collapse and pleural effusion. (B) Thoracic ultrasound showing an echogenic pleural effusion, diaphragmatic inversion and nodularity. Transverse (C) and coronal (D) computed tomography images confirming complete left lung collapse and an associated pleural effusion.
have shown no significant difference in the 30 day pleurodesis success rate (radiologically measured) between surgical (thoracoscopic) talc insufflation and thoracostomy with talc slurry for patients with documented MPE. However meta-analysis conducted by Xia et al. showed that thoracoscopic talc poudrage was more effective than bedside talc slurry in controlling MPE especially in subjects with life-expectancy longer than one month.

Indwelling pleural catheter (IPC)

An alternative approach is the placement of a long term tunneled IPC. Insertion should be considered as a first-line option alongside pleurodesis and offers patients the choice of outpatient management versus the previous ‘standard’ inpatient drainage and pleurodesis. Their insertion is indicated as the primary treatment for symptomatic MPE patients with an underlying ‘trapped lung’. In RCT Davies et al. compared the effectiveness of IPC with chest tube and talc slurry pleurodesis. There was no observed difference in the primary outcome measure, daily visual analogue scale scores of dyspnoea over 42 days, with both groups reporting an improvement in dyspnoea from baseline. Length of hospitalisation over the 12 month study period was significantly shorter in the IPC group than the talc group (~3.5 days, p<0.001). There was no significant difference in quality of life or in the mean cost of managing patients with IPCs compared with talc pleurodesis. Furthermore, for patients with a survival of <14 weeks, IPC was significantly less costly than talc pleurodesis. Although complications were higher in the IPC group in this study, other authors have reported low rates of IPC related adverse effects. In the meta-analysis by Van Meter et al. compared the rates of empyema (2.8%), pneumothorax (5.9%), cellulitis (3.4%), catheter obstruction/blockage (3.7%) and unspecified malfunction of the catheter (9.1%) were all low and use of an IPC was without complication in the majority (87.3%) of patients. There is ongoing multicentre RCT which aims to compare the efficacy of an IPC placement versus IPC placement plus talc sclerosant in patients with MPE managed exclusively as outpatients (IPC-PLUS). The primary outcome is successful pleurodesis at five weeks post-randomisation. Initial data based on 24 patients with a symptomatic MPE who underwent talc pleurodesis via IPCs confirmed the safety and efficacy of administering talc slurry through IPCs in an outpatient setting.

Conclusions

The decision to undertake definitive therapy (pleurodesis, IPC, or both) for MPEs is decided on a case-by-case basis. The goals should concentrate on the prompt relief of symptoms, minimizing discomfort and disruption of the patient’s everyday life. There are several effective therapeutic interventions available for patients with recurrent MPE which might be combined to achieve optimal control of symptoms.

The ultimate decision as to which strategy to adopt should be made following dialogue between the patient and the managing physicians, supported by the multi-disciplinary team.

No consensus exists regarding the ideal timing of definitive treatment of MPE in patients with chemoimmune disease; at present, this remains at the discretion of the individual physician and patient. Further research is required.

References